Nine Chapters Capital Management’s Meridian Bioscience Inc VIVO Stock Holding History

Nine Chapters Capital Management’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	$166K	Buy	11,600 +700	+6%	+$10K	0.37%	106
2017 Q2	$172K	Sell	10,900 -24,600	-69%	-$354K	1.63%	34
2017 Q1	$490K	Buy	+35,500	New	+$496K	0.66%	41
2014 Q2	–	Sell	-17,600	Closed	-$384K	–	1170
2014 Q1	$384K	Buy	+17,600	New	+$403K	0.05%	528

Other funds holding VIVO

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return

Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Nine Chapters Capital Management's VIVO Position: Q3 2017 in Review

Nine Chapters Capital Management increased its Meridian Bioscience Inc (VIVO) stake by 6.4% in Q3 2017, buying an estimated $10K and bringing the position to 11,600 shares worth $166K. The position accounts for 0.37% of the portfolio, ranked #106.

Nine Chapters Capital Management first reported a position in VIVO in Q1 2014 and has held it in 4 quarters since. The position peaked at $490K in Q1 2017. 172 funds tracked by Wall St. Rank hold VIVO as of Q3 2017.

Nine Chapters Capital Management held 11,600 shares of Meridian Bioscience Inc worth $166K as of Q3 2017.
Nine Chapters Capital Management bought 700 Meridian Bioscience Inc shares in Q3 2017, an estimated $10K.
Meridian Bioscience Inc made up 0.37% of Nine Chapters Capital Management's portfolio in Q3 2017, its #106 holding.
Nine Chapters Capital Management first reported a position in Meridian Bioscience Inc in Q1 2014 and has held it in 4 quarters since.
Nine Chapters Capital Management's Meridian Bioscience Inc position peaked at $490K in Q1 2017.
172 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q3 2017.

Based on Nine Chapters Capital Management's 13F filing for Q3 2017, filed 31 Oct 2017.